PMID- 24649052
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211021
IS  - 2049-9434 (Print)
IS  - 2049-9442 (Electronic)
IS  - 2049-9434 (Linking)
VI  - 1
IP  - 6
DP  - 2013 Nov
TI  - Effects of nateglinide and acarbose on glycemic excursions in standardized 
      carbohydrate and mixed-meal tests in drug-naive type 2 diabetic patients.
PG  - 913-917
AB  - The aim of this study was to compare the effects of nateglinide and acarbose on 
      glycemic excursions and postprandial glucose profiles with different types of 
      meals (standardized carbohydrate and mixed meals) in drug-naive type 2 diabetic 
      patients. A randomized, parallel-group prospective design clinical trial was 
      conducted and a total of 39 drug-naive patients (16 males and 23 females, aged 
      56.7+/-10.2 years) were enrolled. The patients were randomly divided into group A 
      [nateglinide 120 mg three times daily (t.i.d.), n=19] and group B (acarbose 50 mg 
      t.i.d., n=20). The standardized carbohydrate and mixed-meal tests were performed 
      at baseline and at the end of study. Continuous glucose monitoring system (CGMS) 
      data were recorded. Various parameters that measure glucose variability were 
      derived from the CGMS data. In the standardized carbohydrate meal tests, the 
      postprandial glucose excursions (PPGEs) were significantly decreased in the two 
      groups after 12 weeks of treatment (P<0.05), whereas the decrease was more 
      prominent in the acarbose compared to the nateglinide group (P=0.138). In the 
      mixed-meal tests, the mean sensor glucose values [24-h mean blood glucose (MBG)] 
      were significantly decreased in the two groups after 12 weeks of treatment 
      (P<0.05) and the parameters of glucose excursions, including standardized 
      deviation (SD), largest amplitude of glycemic excursion (LAGE), mean of daily 
      differences (MODD) and mean amplitude of glycemic excursion (MAGE), were reduced 
      in the two groups. However, the decreases in SD and LAGE in the nateglinide group 
      were statistically significant, whereas in the acarbose group only the decreases 
      in LAGE were statistically significant. The efficiency of nateglinide or acarbose 
      in lowering postprandial 120-min hyperglycemia were similar in the standardized 
      carbohydrate meal test. However, acarbose was more efficient in lowering 
      postprandial 30- and 60-min hyperglycemia (P<0.05) compared to nateglinide. The 
      fasting and postprandial total cholesterol (TC), triglyceride (TG) and 
      low-density lipoprotein cholesterol (LDL-C) had a tendency to decrease from the 
      baseline after 12 weeks of treatment with nateglinide, whereas fasting and 
      postprandial high-density lipoprotein cholesterol (HDL-C) had a tendency to 
      increase. Acarbose did not affect the fasting or postprandial lipid profiles 
      after 12 weeks of treatment (P>0.05). In conclusion, nateglinide and acarbose 
      effectively improved postprandial glycemic control, although acarbose was shown 
      to be more efficient in controlling early (30 and 60 min) postprandial glucose 
      excursions in the carbohydrate meal test, whereas nateglinide was shown to be 
      superior to acarbose in controlling postprandial glucose excursions in the 
      mixed-meal test.
FAU - Li, Hai
AU  - Li H
AD  - Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of 
      Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R. China.
FAU - Xu, Wenming
AU  - Xu W
AD  - Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of 
      Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R. China.
FAU - Liu, Juan
AU  - Liu J
AD  - Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of 
      Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R. China.
FAU - Chen, Ailing
AU  - Chen A
AD  - Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of 
      Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R. China.
FAU - Liao, Zhihong
AU  - Liao Z
AD  - Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of 
      Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R. China.
FAU - Li, Yanbing
AU  - Li Y
AD  - Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of 
      Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20130807
PL  - England
TA  - Biomed Rep
JT  - Biomedical reports
JID - 101613227
PMC - PMC3917008
OTO - NOTNLM
OT  - acarbose
OT  - glycose excursion
OT  - nateglinide
OT  - postprandial glucose
OT  - type 2 diabetes mellitus
EDAT- 2014/03/22 06:00
MHDA- 2014/03/22 06:01
PMCR- 2013/08/07
CRDT- 2014/03/21 06:00
PHST- 2013/04/21 00:00 [received]
PHST- 2013/07/03 00:00 [accepted]
PHST- 2014/03/21 06:00 [entrez]
PHST- 2014/03/22 06:00 [pubmed]
PHST- 2014/03/22 06:01 [medline]
PHST- 2013/08/07 00:00 [pmc-release]
AID - br-01-06-0913 [pii]
AID - 10.3892/br.2013.156 [doi]
PST - ppublish
SO  - Biomed Rep. 2013 Nov;1(6):913-917. doi: 10.3892/br.2013.156. Epub 2013 Aug 7.